Abstract: The present invention relates to the technical field of chemical drug synthesis, and specifically relates to a method for preparing a compound as shown in formula I, comprising: treating the compound as shown in formula VII with an acid to generate the compound as shown in formula I. The method has few synthetic process steps, raw materials which is stable and is easy to prepare, a reaction process which is easy to control, and a high overall yield and purity, and is suitable for industrial preparation.

Abstract: The invention relates to a compound represented by general Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable hydrate thereof or pharmaceutically acceptable solvate thereof and the invention also relates to a pharmaceutical composition comprising the compound, and a preparation method for the compound and a use of the compound.

Abstract: The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.

Abstract: The present invention relates to an application of benflumetol and derivatives thereof in treatment of coronavirus infection, and specifically provides uses of a compound represented by formula A, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of drugs. The drugs are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2).

Abstract: Disclosed is a relay selection method for unmanned aerial vehicles in post disaster emergency scenarios in underground space, comprising the following steps: collecting a maximum rate, a minimum rate and an average rate of data transmission assisted by a D2D user through an unmanned aerial vehicle (UAV) based on a prediction range of the D2D user for the UAV, and obtaining a first uncertain preference order of the D2D user for the UAV and a second uncertain preference order of the UAV for the D2D user; obtaining a preference strategy of the D2D user for the UAV based on the first uncertain preference order and the second uncertain preference order; and exchanging and matching the UAVs matched by any two D2D users based on the many-to-one bilateral matching model, so as to obtain a stable matching result of bilateral exchange.

Abstract: Disclosed is a method for preparing a C-nucleoside compound represented by Formula (III) or salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature conditions, does not require frequent changes to the reaction system during the operation process, is suitable for scale-up synthesis, is suitable for large-scale production of Remdesivir, and has low costs.

Abstract: Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.

Abstract: Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.

Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.

Abstract: The invention relates to the technical fields of binaural audio rendering and, to this end, estimation of room acoustic parameters like reverberation time. In particular, the invention provides a device and method for estimating such acoustic parameters. The device is configured to record an acoustic signal, particularly a speech signal, to estimate a frequency-dependent reverberation time in a lower frequency range based on the recorded acoustic signal, and to extend the frequency-dependent reverberation time to a higher frequency range based on a predetermined model to obtain an extended frequency-dependent reverberation time. Virtual 3D audio can thus be adapted to a real room.

Abstract: The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.

Abstract: Disclosed are a pyrazole compound or a salt thereof, a preparation method therefor, a herbicidal composition and use thereof. The pyrazole compound or a salt thereof has a structure as shown in formula (I): wherein, R represents wherein, R?, R?, and R?? represent hydrogen, C1-C4 alkyl, C1-C4 halogenated alkyl, C1-C4 alkoxy or halogen, R?, R?, and R?? may be the same or different; R1 represents C1-C3 alkyl; R2 represents hydrogen or C1-C4 alkyl; R3 represents hydrogen or C1-C6 alkyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted alkenyl, optionally substituted alkynyl, C1-C6 alkyl carbonyl, C1-C6 alkoxyl carbonyl, C1-C6 alkyl carbonyl methyl, etc. A compound having a pyrazole structure not only has excellent herbicidal effect on barnyard grass, but also is safe to rice in post-emergence application. More surprisingly, it also has good control efficacy on barnyard grass resistant to major herbicides, such as penoxsulam, quinclorac, cyhalofop-butyl, propanil, etc.

Abstract: A beam scanning apparatus with arrayed rotating mirrors is provided. The beam scanning apparatus includes a motor, a worm, a wormgear, a mounting rack, and a rotating mirror, where the worm and the wormgear are located on the mounting rack, and engage with each other by using a gear for a linkage connection; the rotating mirror is located in the mounting rack, and is coaxially connected to the wormgear; and the motor is configured to drive the worm to rotate, to drive the wormgear and the rotating mirror to rotate coaxially. The rotating mirror may be replaced with another rotating mirror with a different structure and a different optical parameter, to adjust output performance of the beam scanning apparatus, thereby improving extensibility.

Abstract: A method for network access, a terminal, and a storage medium are provided. The method includes that: the terminal acquires a first frequency band corresponding to a first cell where the terminal camps; determines whether the first frequency band belongs to a second frequency band predetermined by the terminal; and performs handover to a second cell which is different from the first cell in response to determining that the first frequency band does not belong to the second frequency band.

Abstract: A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,

Abstract: The present application provides a recombinant fusion protein containing an anti-CD38 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD38 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD38 using the recombinant fusion protein.

Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.

Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.

Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.

Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.